Dichlororibofuranosylbenzimidazole (DRB)

Subscribe to Selected New Research on Dichlororibofuranosylbenzimidazole

198 relevant articles (3 outcomes, 26 trials/studies) found for this Bio-Agent

Description: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.

Also Known As:

DRB; 5,6-Dichloro-1-beta-D-ribofuranosyl-1-H-benzimidazol; 5,6-Dichloro-1-beta-ribofuranosylbenzimidazole; 5,6 Dichloro 1 beta D ribofuranosyl 1 H benzimidazol; 5,6 Dichloro 1 beta ribofuranosylbenzimidazole; Riboside, Dichlorobenzimidazole; Dichlorobenzimidazole Riboside; 1H-Benzimidazole, 5,6-dichloro-1-beta-D-ribofuranosyl-

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1

Nucleosides: 591

Ribonucleosides: 30

Dichlororibofuranosylbenzimidazole: 198

5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole-3',5'-monophosphorothioate: 1

Experts

1.	Sauermann, U: 2 articles (10/2008 - 09/2000)
2.	Jiao, Jian: 2 articles (02/2005 - 10/2003)
3.	Goljan, A: 2 articles (01/2000 - 01/2000)
4.	Sankowska, M: 2 articles (01/2000 - 01/2000)
5.	Zieliński, J: 2 articles (01/2000 - 01/2000)
6.	Puścińska, E: 2 articles (01/2000 - 01/2000)
7.	North, D: 1 article (10/2008)
8.	Mee, E T: 1 article (10/2008)
9.	Murrell, C K: 1 article (10/2008)
10.	Rose, N J: 1 article (10/2008)

Related Diseases

1.	Rheumatoid Arthritis 10/01/2003 - "Proteus mirabilis (PM) is implicated in different studies in the pathogenesis of rheumatoid arthritis (RA) because of the structural homogeneity of its haemolysin B precursor with EQRRAA sequences in DRB 1 haplotype" 09/01/2003 - "Proteus mirabilis(PM) is implicated in different studies in the pathogenesis of rheumatoid arthritis (RA) because of the structural homogeneity of its haemolysin B precursor with EQRRAA sequences in DRB 1 haplotype" 01/01/1996 - "This study analyses the prognostic value of HLA-DRB 1 genes for Swiss patients with rheumatoid arthritis (RA)" 12/01/2006 - "HLA-DRB genotyping of an Italian mummy from the 16th century with signs of rheumatoid arthritis." 04/01/2004 - "Predisposition to rheumatoid arthritis has been associated with major histocompatibility complex (MHC) class II genes, HLA-DRB0401/DQB10302 and resistance to DRB10402 and DQ6 genes" Get all the results and reference details, order at left...*
2.	Shock 07/10/1998 - "Following heat-shock treatment, the transcription of non-heat-shock genes was completely eliminated, while newly formed heat-shock gene transcripts emerged in a DRB-resistant manner" 01/01/2005 - "Results are consistent with the second (DRB-insensitive but heat-shock-sensitive) fraction being bound but not engaged, while the third (sensitive to both DRB and heat shock) is the elongating hyperphosphorylated form (i.e" 07/10/1998 - "This phosphorylation is resistant to DRB treatment, suggesting that not only phosphorylation but also transcription of heat-shock genes is DRB resistant and that CDK7 in heat shock cells is not associated with TFIIH." 11/01/1988 - "The induction of puff III-A3b, a major heat-shock puff in Chironomus thummi salivary cells, was insensitive to the transcription inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), whereas no transcriptional activity could be detected at the other heat-shock puffs in the presence of this drug" 11/01/1988 - "In addition to DRB insensitivity, incorporation of [3H]UTP on puff III-A3b took place in an in vitro transcription assay under low-salt conditions (100 mM NaCl); no labelling could be detected at the other heat-shock puffs under these conditions" Get all the results and reference details, order at left...
3.	Arthritis (Polyarthritis) 02/01/2003 - "The magnitude of OspA(163-175) binding correlated well with the frequencies of the DRB1 alleles in patients with treatment-resistant arthritis, but the binding of hLFA-1alpha(L330-342) showed only an association with the DRB04 alleles" 07/01/1999 - "Co-immunization of the DRB 10402 peptide significantly reduced the severity of arthritis (mean score = 1.5+/-0.6 vs 5.2+/-1.4 in controls), whereas multiple doses of the peptide reduced the incidence of disease (3.5% vs 35-60% in controls)" Get all the results and reference details, order at left...
4.	Infection 05/31/2008 - "The aim of this study is to investigate the role of DRB alleles/haplotypes on resistance/susceptibility to HIV-1 infection" 10/01/2003 - "A simple, rapid method for characterizing FLA-DRB makes possible studies on vaccine response and susceptibility/resistance to viral infections, which are a significant clinical problem in cats." 12/01/2000 - "Study on the relations between HLA-DRB 1 alleles and Helicobacter pylori infection]" 10/01/2008 - "A discordance with SRV-2 infection status suggests that an Mhc II DRB genotype is not overtly associated with the outcome of viral infection." 10/01/2008 - "The Mhc class II DRB genotype of Macaca fascicularis does not influence infection by simian retrovirus type 2." Get all the results and reference details, order at left...
5.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/01/1992 - "Extensive study of DRB, DQA, and DQB gene polymorphism in 23 DR2-positive, insulin-dependent diabetes mellitus patients." 02/01/2003 - "Since her HLA type was A 24, B 13, B 46, CW 1, CW 3, DRB 1[0901/0901], DQB 1[0303/0303], and DPB 1[0201/0201], this patient was regarded as being susceptible to type 1 diabetes mellitus" 03/01/2000 - "When the DRB, DQA or DQB genotypes of the susceptible alleles are compared, the most strong susceptibility marker of the disease is found to be DRB10301/04 (31.4% vs. 2.8%, p < 0.0001, OR: 15.8) and among these, heterozygote genotype DRB10301/0401 (4.5% vs. 0, p = 0.0008, OR: 24.8).These results confirm the positive associations with IDDM previously observed in other Caucasian populations and reveal many negative and strong associations which maybe underlining several characteristics that distinguish Turkish diabetics form other Caucasians." 03/01/2000 - "To extend this data with a population with relatively low IDDM incidence, MHC DRB, DQA, and DQB have been investigated by polymerase chain reaction and sequence specific oligonucleotide probe hybridization (PCR/SSO) in 178 IDDM patients from Turkey and compared to 248 healthy controls" 11/01/1996 - "The frequency of positive response to the coxsackie B viruses was also significantly higher in IDDM subjects expressing the DRB 104 major histocompatibility complex (MHC) haplotype than the DRB 103 haplotype" Get all the results and reference details, order at left...*
111 Diseases and 198 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Carbon Monoxide
2.	Collagen Type II (Type II Collagen)
3.	Antigens
4.	Complementary DNA (cDNA)
5.	HLA-DQB1 (HLA DQB1)
6.	Immunoglobulin E (IgE)
7.	Interferon-alpha (Interferon Alfa)
8.	HLA-DR2 Antigen (HLA DR2 Antigen)
9.	T-Cell Antigen Receptors (T-Cell Receptor)
10.	CD40 Ligand (CD40L)
91 Drugs and Important Bio-Agents and 88 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Transplants (Transplant)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>